Our Approach

Through our research and partnerships, we are helping to shape the real-world evidence industry and advance the field of oncology.

Our collaborations are leading industry to advance the treatment landscape, reimagine the drug development life cycle, and accelerate value-based care models.

Our Research and Publications

Discover more about how our work with the FDA, industry and academia helps to ensure that everyone touched by cancer is given a clear path to the right care.

3 Key Attributes of Every Successful Value-Focused Oncology Practice

Oncology practices, especially providers participating in value-based reimbursement programs from the Centers for Medicare and Medicaid Services (CMS) like the Oncology Care Model (OCM), are under pressure to measure and improve performance.
DOWNLOAD

Prospective Assessment of the Value of Genomic Profiling in Metastatic Lung Cancer

This prospective observational study is designed to reveal genomic profiling patterns and the influence of testing on clinical and economic outcomes among patients with advanced lung cancer in real world settings.
DOWNLOAD

Digital characterization of breast cancer phenotypes to identify variances in care and costs at scale

This study applies the novel Cota Nodal Address (CNA) digital system to a consecutive cohort of patients with breast cancer to identify population frequencies of subtypes and variances in treatment patterns and total costs of care for one year following diagnosis.
DOWNLOAD

Are patients with advanced cancer concerned about financial toxicity?

Cancer patients are more than twice as likely to enter bankruptcy as the general US population. It is unknown how often patients with metastatic cancer are concerned about the financial toxicities of treatment.
DOWNLOAD

Development of a Patient Reported Outcome Instrument to Facilitate Timing of End-of-Life Discussions in Patients with Advanced Cancers

Honoring the wishes of terminally ill cancer patients is a prime responsibility of oncologists, however end of life (EOL) discussions are frequently either never performed or delayed past the point of usefulness.
DOWNLOAD

A new digital classification schema to detect treatment variances and enable value based payment reforms

Value based payment reforms which improve the outcome to cost ration (paying for outcomes not for services) require detailed information on both elements.
DOWNLOAD

COTA in the News

COTA Wins eyeforpharma Health Tech Challenge

COTA Wins eyeforpharma Health Tech Challenge

Every pharma company wants to work with startups – for good reason. Startups work with agility to find solutions that often address patients’ unmet needs. As our industry commits to providing more patient value, eyeforpharma is committed to showcasing the brightest and best startups.
READ MORE
How Stratified Patient Data and Electronic Health Records Can Help Improve Cancer Care

How Stratified Patient Data and Electronic Health Records Can Help Improve Cancer Care

Oncologists do incredible work to save lives, however, there is more to be done to help support the people who are making the most important decisions at the most critical inflection points.
READ MORE
COTA Signs Research Agreement with the FDA

COTA Signs Research Agreement with the FDA

COTA signs a two-year Research Collaboration Agreement (RCA) with the FDA to study variation in cancer treatment patterns using real-world data. This RCA will provide the FDA with information on the evolving breast cancer treatment landscape, including insight on treatment variation.
READ MORE
FDA Leverages Private Sector Technology Based Tools In Its Embrace Of Real World Evidence

FDA Leverages Private Sector Technology Based Tools In Its Embrace Of Real World Evidence

Following decades of near total reliance on randomized clinical trial data, the U.S. Food & Drug Administration (with a helpful nudge from the Congress) is accessing private sector technology based tools as a means of incorporating real world data (RWD) and evidence (RWE) into its drug approval, label expansion and regulatory oversight tasks.
READ MORE
How to apply real-world evidence to outsmart cancer

How to apply real-world evidence to outsmart cancer

Cancer, one of the most complex diseases we face today, is a challenge to study and treat. The once carefully ordered world of cancer diagnosis and treatment — breast cancer is one thing, lung cancer is another — has been upended by genetic analyses.
READ MORE
NY health data firm moving its headquarters to Boston

NY health data firm moving its headquarters to Boston

A New York-based startup that mines health care data to determine what cancer medicine would work best for a particular patient — and be most cost effective — is moving its headquarters to Boston. COTA, which was founded in 2011 by doctors, engineers, and data scientists, next week plans to open at 101 Arch St., in Downtown Crossing.
READ MORE

Press Releases

Initial Results of Real-World Evidence Pilot Study Published in JCO Clinical Cancer Informatics

READ MORE

COTA Announces Headquarter Relocation to Boston for Continued Growth

READ MORE

COTA Welcomes Daniel Lane as Vice President for HEOR to Drive Outcomes-Based Research in Oncology

READ MORE

COTA Signs Research Collaboration Agreement With The U.S. Food and Drug Administration

READ MORE

COTA Brings on Innovative Veteran CEO to Drive Next Phase of Growth and Delivery of Breakthrough Technology and Insights

READ MORE

COTA Increases Breakthrough Capability, adds Chief Technology Officer

READ MORE

Our collective responsibility
to apply real-world evidence

FDA and COTA recently finalized a research collaboration agreement. Research efforts are underway across tumor types to assess the utility of RWE in drug development for high unmet need populations and in accelerating clinical trials.

Friends of Cancer Research and COTA partnered in a pilot study of immune checkpoint inhibitors approved for non-small cell lung cancer to define a standard data framework and to assess correlation between real-world endpoints and overall survival.

Let’s work together to transform cancer care.

CONTACT US

Bringing clarity
to cancer

We are working to ensure that everyone touched by cancer has a clear path to the right care.